Avenue Therapeutics Ownership
| ATXI Stock | USD 2.01 0.04 2.03% |
Shares in Circulation | First Issued 2016-03-31 | Previous Quarter 1.1 M | Current Value 1.6 M | Avarage Shares Outstanding 2.2 M | Quarterly Volatility 4.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Avenue |
Avenue Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 1.47. Some equities with similar Price to Book (P/B) outperform the market in the long run. Avenue Therapeutics recorded earning per share (EPS) of 24.78. The entity had not issued any dividends in recent years. The firm had 1:75 split on the 26th of April 2024. Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acuteintensive care hospital setting. The company was incorporated in 2015 and is based in New York, New York. Avenue Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. For more info on Avenue Therapeutics please contact the company at 781 652 4500 or go to https://www.avenuetx.com.Besides selling stocks to institutional investors, Avenue Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Avenue Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Avenue Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Avenue Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Avenue Therapeutics Insider Trades History
About 10.0% of Avenue Therapeutics are currently held by insiders. Unlike Avenue Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Avenue Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Avenue Therapeutics' insider trades
Avenue Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avenue Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avenue Therapeutics backward and forwards among themselves. Avenue Therapeutics' institutional investor refers to the entity that pools money to purchase Avenue Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-06-30 | 75 K | Sabby Management Llc | 2024-06-30 | 37.4 K | Moss Adams Wealth Advisors Llc | 2024-09-30 | 11 K | Tower Research Capital Llc | 2024-06-30 | 3.2 K | Ubs Group Ag | 2024-06-30 | 673 | Wells Fargo & Co | 2024-06-30 | 61.0 | Royal Bank Of Canada | 2024-06-30 | 8.0 | Emfo, Llc | 2024-06-30 | 8.0 | Bank Of America Corp | 2024-06-30 | 7.0 | Jpmorgan Chase & Co | 2024-06-30 | 1.0 |
Avenue Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avenue Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avenue Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avenue Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avenue Therapeutics Outstanding Bonds
Avenue Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Avenue Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Avenue bonds can be classified according to their maturity, which is the date when Avenue Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| AVNT 7125 01 AUG 30 Corp BondUS05368VAA44 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US05367AAH68 Corp BondUS05367AAH68 | View | |
| AVIAGP 9 01 DEC 28 Corp BondUS05368PAA75 | View | |
| AVERY DENNISON P Corp BondUS053611AJ82 | View | |
| AVY 225 15 FEB 32 Corp BondUS053611AM12 | View | |
| US053611AK55 Corp BondUS053611AK55 | View |
Avenue Therapeutics Corporate Filings
F3 | 15th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 7th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share 24.78 | Return On Assets (2.01) | Return On Equity (5.35) |
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.